Kyle Rasbach

Dr. Rasbach is a managing partner at Pappas Capital. He joined the organization in 2018, bringing with him extensive experience in clinical pharmacology, basic science and healthcare equity research. Kyle currently serves as a director for Allievex and Balance Therapeutics, and as a board observer for CuraSen Therapeutics, Ribometrix and VelosBio. He previously served as an observer for Mirum Pharmaceuticals. Kyle also serves on the boards of the Council for Entrepreneurial Development (CED) and the NC Biosciences Organization (NCBIO).

​Prior to joining Pappas, Kyle was an equity research analyst and Vice President at T. Rowe Price in Baltimore, where he managed pharmaceutical, specialty pharmaceutical and biotechnology investments for all T. Rowe Price funds. Prior to joining T. Rowe, he was an equity research associate and Vice President at Cowen and Company in Boston, where he covered global pharmaceutical equities.

Kyle has a number of advanced degrees including a PhD in Pharmaceutical and Biomedical Sciences and a Doctor of Pharmacy/PharmD (both from Medical University of South Carolina), as well as an MBA from The Citadel. He completed his postdoctoral work in the laboratory of Bruce Spiegelman at Harvard Medical School, where he contributed to a number of high profile publications, including papers in Cell, Cell Metabolism, Nature and PNAS.